PEPTOKING
EN

ESC heart failure guidelines back semaglutide or tirzepatide in HFpEF with obesity

Research

The European Society of Cardiology published its 2026 heart failure guidelines at ESC Congress 2026. They add a Class IIa recommendation for semaglutide or tirzepatide in people with heart failure with preserved ejection fraction (HFpEF) and obesity. The guidelines also give mineralocorticoid receptor antagonists a Class I recommendation in chronic heart failure regardless of ejection fraction.

Sources

  1. 012026 ESC Guidelines for the management of heart failure(opens the source in a new tab) European Society of Cardiology
  2. 022026 ESC Guidelines for the management of heart failure(opens the source in a new tab) European Heart Journal

Peptides involved

  1. ApprovedSemaglutideGLP-1 receptor agonist31
  2. ApprovedTirzepatideDual GIP and GLP-1 receptor agonist39